Daewoong Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 14, 2023 at 01:45 am EDT
Share
Daewoong Co., Ltd. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was KRW 469,420.62 million compared to KRW 422,065.22 million a year ago. Net income was KRW 37,123.98 million compared to KRW 32,024.16 million a year ago. Basic earnings per share from continuing operations was KRW 893 compared to KRW 770 a year ago. Basic earnings per share was KRW 893 compared to KRW 770 a year ago.
For the six months, sales was KRW 8,967.51 million compared to KRW 7,496.39 million a year ago. Net income was KRW 75,553.9 million compared to KRW 55,472.7 million a year ago. Basic earnings per share from continuing operations was KRW 1,817 compared to KRW 1,334 a year ago. Basic earnings per share was KRW 1,817 compared to KRW 1,334 a year ago.
Daewoong Co Ltd is a Korea-based holding company engaged in the manufacture and sale of pharmaceuticals. The Company operates its business mainly through subsidiaries including Daewoong Pharmaceutical Co Ltd, Daewoong Bio Co Ltd, Daewoong Development Co Ltd, and Hanall Biopharma Co Ltd. Daewoong Pharmaceutical Co Ltd, Daewoong Bio Co Ltd and Hanall Biopharma Co Ltd are engaged in the manufacture and sale of pharmaceuticals. Daewoong Development Co Ltd is engaged in real estate rental and supply business. In addition, IDS&Trust Co Ltd manufactures and sells communication-related devices. Daewoong Life Science Co Ltd is engaged in food processing and sales. Pampaeg Co Ltd is engaged in the packaging business of quasi-drugs. Daewoong Management Development Institute Co Ltd is engaged in management and industrial training projects.
DAEWOONG CO., LTD. 
